Presentations From Further Progress in Management of CINV - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations From Further Progress in Management of CINV

Searching for Perfection

Not a member of My prIME? Join now for instant access.

Get up-to-date in the management of chemotherapy-induced nausea and vomiting (CINV) with these presentation slides from our symposium held in conjunction with the 2017 Multinational Association for Supportive Care in Cancer (MASCC) and International Society of Oral Oncology (ISOO) Annual Meeting.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jun 28, 2017

Expiration Date

Jun 28, 2018

Featured Expert

  • Matti Aapro, MD, Multidisciplinary Oncology Institute, Genolier, Switzerland

Featured Topic

CINV: Still troubling patients after all these years

Featured Expert

  • Mark Clemons, MD, The Ottawa Hospital Cancer Centre
    University of Ottawa, Ottawa, Ontario, Canada

Featured Topic

Guidelines versus individualized care for management of CINV

Featured Expert

  • Lee Schwartzberg, MD, FACP, West Cancer Center, Memphis, Tennessee, United States

Featured Topic

Getting it right the first time: Recent progress in optimizing antiemetic usage

Featured Expert

  • David Warr, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Featured Topic

Bringing it all together: Application of current knowledge into routine clinical practices

This educational activity is specifically designed to meet the needs of oncologists, registered nurses, and other healthcare professionals involved in the treatment of patients with CINV.

After successful completion of this educational activity, participants should be able to:

  • Identify the treatment and patient risk factors for CINV
  • Determine the role of a CINV risk factor toolkit to optimize individual patient management
  • Describe recent clinical trial data evaluating neurokinin-1 (NK-1) receptor antagonists
  • Incorporate recent changes to the clinical guidelines for CINV management into routine practice

This educational activity is supported by grants from Merck and Co, Inc. and TESARO, Inc.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.